CCN1 and pancreatic neoplasm: For resectable pancreatic tumors, the standard of care involves surgery followed by adjuvant chemotherapy, typically using a combination of gemcitabine plus capecitabine.[45] However, chemoresistance is common, posing a significant threat to the long‐term survival of pancreatic cancer patients.[46] To investigate whether Ccn1‐deficient KPC cells are sensitive to gemcitabine, we treated these cells alongside control cells with gemcitabine.